Added Factors Put the Overall Survival Endpoint to the Test

Maurie Markman, MD
Published: Thursday, Jan 03, 2019
Maurie Markman, MD

Maurie Markman, MD
The debate continues: How can a new antineoplastic agent be approved for marketing if it has not been demonstrated in at least 1 well-designed phase III randomized clinical trial to offer a statistically significantly overall survival (OS) advantage? Is it possible to disagree with the simple logic that this endpoint must be the major aim of all antineoplastic agents, to improve the survival of patients receiving the drug? After all, isn’t this what patients want to achieve, the greatest possible duration of survival?
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication